Nonalcoholic fatty liver disease and elastography: Incremental advances but work still to be done
William N. Hannah, Stephen A. Harrison – 18 February 2016
The many faces of positive hepatitis B surface antigen
Derek M. Tang, Theo Heller, Christopher Koh – 18 February 2016
Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES
Tracey G. Simon, Hector Bonilla, Peng Yan, Raymond T. Chung, Adeel A. Butt – 18 February 2016 – Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most effective type and dose of statin in this population. We sought to determine the impact of statin type and dose upon fibrosis progression and HCC in patients with HCV.
Quality of care metrics in chronic hepatitis B
Jessica Mellinger, Robert J. Fontana – 18 February 2016
The impact of broader regional sharing of livers: 2‐year results of “Share 35”
Erick B. Edwards, Ann M. Harper, Ryutaro Hirose, David C. Mulligan – 17 February 2016 – In June of 2013, the Organ Procurement and Transplantation Network (OPTN) implemented regional sharing for Model for End‐Stage Liver Disease (MELD)/Pediatric End‐Stage Liver Disease (PELD) candidates with scores reaching 35 and above (“Share 35”). The goal of this distribution change was to increase access to lifesaving transplants for the sickest candidates with chronic liver disease and to reduce the waiting‐list mortality for this medically urgent group of patients.
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
Robert J. Fontana, Robert S. Brown, Ana Moreno‐Zamora, Martin Prieto, Shobha Joshi, Maria‐Carlota Londoño, Kerstin Herzer, Kristina R. Chacko, Rudolf E. Stauber, Viola Knop, Syed‐Mohammed Jafri, Lluís Castells, Peter Ferenci, Carlo Torti, Christine M. Durand, Laura Loiacono, Raffaella Lionetti, Ranjeeta Bahirwani, Ola Weiland, Abdullah Mubarak, Ahmed M. ElSharkawy, Bernhard Stadler, Marzia Montalbano, Christoph Berg, Adriano M. Pellicelli, Stephan Stenmark, Francis Vekeman, Raluca Ionescu‐Ittu, Bruno Emond, K.
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension
Sílvia Vilarinho, Sinan Sari, Güldal Yilmaz, Amy L. Stiegler, Titus J. Boggon, Dhanpat Jain, Gulen Akyol, Buket Dalgic, Murat Günel, Richard P. Lifton – 13 February 2016 – Despite advances in the diagnosis and management of idiopathic noncirrhotic portal hypertension, its pathogenesis remains elusive. Insight may be gained from study of early‐onset familial idiopathic noncirrhotic portal hypertension, in which Mendelian mutations may account for disease.
Liver capsule: Mechanisms of alcoholic hepatitis
Bernd Schnabl – 11 February 2016
Liver capsule: Mechanisms of alcoholic hepatitis
Bernd Schnabl – 11 February 2016
Is increased hepatitis C virus case‐finding combined with current or 8‐week to 12‐week direct‐acting antiviral therapy cost‐effective in UK prisons? A prevention benefit analysis
Natasha K. Martin, Peter Vickerman, Iain F. Brew, Joan Williamson, Alec Miners, William L. Irving, Sushma Saksena, Sharon J. Hutchinson, Sema Mandal, Eamonn O'Moore, Matthew Hickman – 10 February 2016 – Prisoners have a high prevalence of hepatitis C virus (HCV), but case‐finding may not have been cost‐effective because treatment often exceeded average prison stay combined with a lack of continuity of care. We assessed the cost‐effectiveness of increased HCV case‐finding and treatment in UK prisons using short‐course therapies.